Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor. In addition, it offers MedChem Studio, a software tool for data mining and designing new molecules; KIWI, a cloud-based Web application, which organizes, processes, maintains, and communicates the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; and DILIsym, a software that is used to investigate the likelihood that a known drug molecule would cause injury to the liver. Further, the company provides consulting services ranging from early drug discovery through preclinical and clinical trial data analysis, and for submissions to regulatory agencies; and population modeling and simulation contract research services for the pharmaceutical and biotechnology industries. Additionally, it offers its pharmaceutical/chemistry software to pharmaceutical, biotechnology, agrochemical, and food companies. Simulations Plus, Inc. was founded in 1996 and is headquartered in Lancaster, California.
Industry, Sector and Symbol
Industry Computer integrated systems design
Sub-IndustryN/A
SectorComputer and Technology
SymbolNASDAQ:SLP
CUSIPN/A
Phone661-723-7723
Debt
Debt-to-Equity RatioN/A
Current Ratio2.78
Quick Ratio2.78
Price-To-Earnings
Trailing P/E Ratio65.59
Forward P/E Ratio56.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$24.14 million
Price / Sales16.08
Cash Flow$0.4647 per share
Price / Cash48.20
Book Value$1.50 per share
Price / Book14.93
Profitability
EPS (Most Recent Fiscal Year)$0.34
Net Income$5.78 million
Net Margins30.65%
Return on Equity26.19%
Return on Assets18.85%
Miscellaneous
Employees86
Outstanding Shares17,330,000
Simulations Plus (NASDAQ:SLP) Frequently Asked Questions
What is Simulations Plus' stock symbol?
Simulations Plus trades on the NASDAQ under the ticker symbol "SLP."
How often does Simulations Plus pay dividends? What is the dividend yield for Simulations Plus?
Simulations Plus announced a quarterly dividend on Monday, April 9th. Stockholders of record on Wednesday, April 25th will be given a dividend of $0.06 per share on Wednesday, May 2nd. This represents a $0.24 annualized dividend and a dividend yield of 1.07%. The ex-dividend date is Tuesday, April 24th. View Simulations Plus' Dividend History.
How were Simulations Plus' earnings last quarter?
Simulations Plus, Inc. (NASDAQ:SLP) posted its quarterly earnings results on Monday, April, 9th. The technology company reported $0.11 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $0.11. The technology company earned $7.36 million during the quarter, compared to analyst estimates of $7.37 million. Simulations Plus had a return on equity of 26.19% and a net margin of 30.65%. View Simulations Plus' Earnings History.
Who are some of Simulations Plus' key competitors?
Some companies that are related to Simulations Plus include Quality Systems (QSII), Sykes Enterprises (SYKE), VASCO Data Security International (VDSI), Unisys (UIS), Ribbon Communications (RBBN), KEYW (KEYW), Digimarc (DMRC), Agilysys (AGYS), Asure Software (ASUR), Aerohive Networks (HIVE), Travelzoo (TZOO), Borqs Technologies (BRQS), Mattersight (MATR), Crexendo (CXDO) and CSP (CSPI).
Who are Simulations Plus' key executives?
Simulations Plus' management team includes the folowing people:
- Mr. Walter S. Woltosz, Chairman & CEO (Age 73)
- Mr. John R. Kneisel, Chief Financial Officer (Age 60)
- Ms. Virginia E. Woltosz, Sec. & Treasurer (Age 67)
- Mr. John Anthony DiBella, Pres of the Lancaster Division (Age 38)
- Dr. Thaddeus Henry Grasela Jr., PharmD, Ph.D., Pres of Cognigen Corp. & Director (Age 64)
Has Simulations Plus been receiving favorable news coverage?
Press coverage about SLP stock has trended somewhat positive this week, Accern reports. Accern identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Simulations Plus earned a news impact score of 0.17 on Accern's scale. They also gave media coverage about the technology company an impact score of 45.71 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Simulations Plus' major shareholders?
Simulations Plus' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.35%), Dimensional Fund Advisors LP (2.74%), Punch & Associates Investment Management Inc. (2.24%), Crawford Investment Counsel Inc. (2.24%), Ancora Advisors LLC (1.71%) and Russell Investments Group Ltd. (0.47%). Company insiders that own Simulations Plus stock include Argenio David Z D, John Robert Kneisel, Thaddeus Henry Grasela Jr, Virginia E Woltosz and Walter S Woltosz. View Institutional Ownership Trends for Simulations Plus.
Which major investors are selling Simulations Plus stock?
SLP stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, PNC Financial Services Group Inc., Stanley Laman Group Ltd., Punch & Associates Investment Management Inc., BlackRock Inc. and JPMorgan Chase & Co.. Company insiders that have sold Simulations Plus company stock in the last year include John Robert Kneisel and Walter S Woltosz. View Insider Buying and Selling for Simulations Plus.
Which major investors are buying Simulations Plus stock?
SLP stock was purchased by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, Millennium Management LLC, Russell Investments Group Ltd., Dimensional Fund Advisors LP, Ancora Advisors LLC, UBS Group AG, Wells Fargo & Company MN and Citigroup Inc.. View Insider Buying and Selling for Simulations Plus.
How do I buy shares of Simulations Plus?
Shares of SLP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Simulations Plus' stock price today?
One share of SLP stock can currently be purchased for approximately $22.40.
How big of a company is Simulations Plus?
Simulations Plus has a market capitalization of $388.10 million and generates $24.14 million in revenue each year. The technology company earns $5.78 million in net income (profit) each year or $0.34 on an earnings per share basis. Simulations Plus employs 86 workers across the globe.
How can I contact Simulations Plus?
Simulations Plus' mailing address is 42505 10TH STREET WEST, LANCASTER CA, 93534. The technology company can be reached via phone at 661-723-7723 or via email at [email protected]
MarketBeat Community Rating for Simulations Plus (SLP)
MarketBeat's community ratings are surveys of what our community members think about Simulations Plus and other stocks. Vote "Outperform" if you believe SLP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLP will underperform the S&P 500 over the long term. You may vote once every thirty days.
